TP53 and B-cell non-Hodgkin lymphoma: TP53 mutations are frequently observed in diffuse large B-cell lymphoma (DLBCL) and refractory/relapsed aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL), where they are strongly associated with poor prognosis, treatment resistance, and relapse (17).